RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Citius Pharmaceuticals Stock

Citius Pharmaceuticals Stocks 2024

Citius Pharmaceuticals Stocks

6.05 M

Ticker

CTXR

ISIN

US17322U2078

WKN

A2DXS0

In 2024, Citius Pharmaceuticals had 6.05 M outstanding stocks, a 0% change from the 6.05 M stocks in the previous year.

The Citius Pharmaceuticals Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2030e6.05
2029e6.05
2028e6.05
2027e6.05
2026e6.05
2025e6.05
2024e6.05
20236.05
2022146.08
2021108.6
202039.17
201920.16
201810.73
20175.48
20163.62
20152.12
20141.29
20130.75
20120.75
20110.75

Citius Pharmaceuticals shares outstanding

The number of shares was Citius Pharmaceuticals in 2023 — This indicates how many shares 6.052 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Citius Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Citius Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Citius Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Citius Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Citius Pharmaceuticals Aktienanalyse

What does Citius Pharmaceuticals do?

Citius Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapies for unmet medical needs. The company was founded in 2006 and is headquartered in Cranford, New Jersey. Business Model Citius Pharmaceuticals' business model is based on the development of drugs and therapies for rare and unmet medical needs. The company utilizes its industry experience and knowledge to identify unmet medical needs and develop novel therapeutic approaches. Citius Pharmaceuticals collaborates closely with leading academic and scientific institutions to expedite and enhance the effectiveness of its development projects. History Citius Pharmaceuticals was founded by Myron Holubiak, who has over 30 years of experience in the pharmaceutical and biotech industry. Holubiak previously led drug development efforts for companies such as 3M Pharmaceuticals and Elan Pharmaceuticals. In 2007, Citius Pharmaceuticals went public to raise capital for its development projects. Products and Divisions Citius Pharmaceuticals operates in two main divisions: the first focuses on the development of drugs for rare and unmet medical needs, while the second concentrates on the development of therapies for common conditions such as hemorrhoids and cold sores. One of Citius Pharmaceuticals' products is Mino-Lok®, a medication for the treatment of severe intravenous catheter infections. This product is designed to reduce the need for antibiotics commonly used in such infections. Mino-Lok® is currently in Phase III clinical development. Another product by Citius Pharmaceuticals is Halo-Lido, a new therapy for hemorrhoids. It contains lidocaine and hydrocortisone acetate, and is developed to reduce pain and inflammation associated with hemorrhoids. Halo-Lido has already been approved by the US Food and Drug Administration (FDA) and is currently available on the market. Additionally, Citius Pharmaceuticals has a portfolio of patented and trademarked products that provide a platform for future growth. The company is also working on the development of new therapies for cold sores and other viral infections. Conclusion Citius Pharmaceuticals Inc. is an innovative biopharmaceutical company that identifies the needs of unmet medical areas and develops innovative solutions for treating these conditions. With an experienced management team and a strong portfolio of patented products, Citius Pharmaceuticals is well positioned to continue growing and increasing value for its stakeholders. Citius Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Citius Pharmaceuticals's Shares Outstanding

Citius Pharmaceuticals's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Citius Pharmaceuticals’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Citius Pharmaceuticals’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Citius Pharmaceuticals’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Citius Pharmaceuticals stock

How many stocks are there of Citius Pharmaceuticals?

The current number of stocks of Citius Pharmaceuticals is 6.05 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Citius Pharmaceuticals are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Citius Pharmaceuticals evolved in recent years?

The number of shares of Citius Pharmaceuticals has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Citius Pharmaceuticals as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Citius Pharmaceuticals?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Citius Pharmaceuticals pay?

Over the past 12 months, Citius Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Citius Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Citius Pharmaceuticals?

The current dividend yield of Citius Pharmaceuticals is .

When does Citius Pharmaceuticals pay dividends?

Citius Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Citius Pharmaceuticals?

Citius Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Citius Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Citius Pharmaceuticals located?

Citius Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Citius Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Citius Pharmaceuticals from 12/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/24/2024.

When did Citius Pharmaceuticals pay the last dividend?

The last dividend was paid out on 12/24/2024.

What was the dividend of Citius Pharmaceuticals in the year 2023?

In the year 2023, Citius Pharmaceuticals distributed 0 USD as dividends.

In which currency does Citius Pharmaceuticals pay out the dividend?

The dividends of Citius Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Citius Pharmaceuticals

Our stock analysis for Citius Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Citius Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.